AEON will be a wholly owned subsidiary of Priveterra and Priveterra will change its name to AEON Biopharma, Inc. Trading is expected to begin on NYSE on July 24, 2023, under the new ticker symbol "AEON" for the New AEON Common Stock following the consummation of the Business Combination, which is expected to occur on July 21, 2023
Save time and jump to the most important pieces.
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
4 - AEON Biopharma, Inc. (0001837607) (Issuer)
- SEC Filing
Priveterra Acquisition Corp (NASDAQ:PMGM) on Monday announced the closing of its business combination with AEON Biopharma. What To Know: Special purpose acquisition company Priveterra has merged with AEON Biopharma. Priveterra changed its name to AEON Biopharma and has commenced trading on the New York Stock Exchange under the ticker "AEON." In addition, AEON announced the closing of funding arrangements of up to $125 million, which includes $50 million of committed financing from existing and new AEON investors, as well as cash from Priveterra's trust account following redemptions. "The capital we have raised through these recent transactions will help fund our clinical development of AB
Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the "Business Combination") with AEON Biopharma, Inc. ("AEON"), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230721427813/en/ The resulting co
NT 10-Q - Priveterra Acquisition Corp. II (0001821606) (Filer)
8-K - Priveterra Acquisition Corp. II (0001821606) (Filer)
NT 10-K - Priveterra Acquisition Corp. II (0001821606) (Filer)
SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)
SC 13G/A - AEON Biopharma, Inc. (0001837607) (Subject)
SC 13D/A - AEON Biopharma, Inc. (0001837607) (Subject)
Priveterra Acquisition Corp. II (NASDAQ:PMGMU, PMGM, PMGMW))) (the "Company") today announced that on April 29, 2024, the Company received a notice (the "10-K Notice") from the staff of the Nasdaq Listing Qualifications department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company had not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rules for continued listing and, accordingly, such delinquency may serve as a separate basis for the delisting of the Company's securities from Nasdaq. The 10-K Notice also states that the Nasdaq Hearings Panel (the "P
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the preventive treatment of episodic migraine is anticipated to readout this fall $50 million financing provides sufficient cash runway to fund operations beyond the anticipated Phase 2 data announcement this fall IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON, AEON WS))), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, annou
Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the "Business Combination") with AEON Biopharma, Inc. ("AEON"), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230721427813/en/ The resulting co